Photodynamic dose does not correlate with long-term tumor response to mTHPC-PDT performed at several drug-light intervals.
Meso-tetra-hydroxyphenyl-chlorin (mTHPC, Foscan), a promising photosensitizer for photodynamic therapy (PDT), is approved in Europe for the palliative treatment of head and neck cancer. Based on work in mice that investigated optimal tumor accumulation, clinical protocols with Foscan typically employ an interval of 96 h between systemic sensitizer administration and irradiation. However, recent studies in mouse tumor models have demonstrated significantly improved long-term tumor response when irradiation is performed at shorter drug-light intervals of 3 and 6 h. Using a previously published theoretical model of microscopic PDT dosimetry and informed by experimentally determined photophysical properties and intratumor sensitizer concentrations and distributions, we calculated photodynamic dose depositions following mTHPC-PDT for drug-light intervals of 3, 6, 24, and 96 h. Our results demonstrate that the singlet oxygen dose to the tumor volume does not track even qualitatively with tumor responses for these four drug-light intervals. Further, microscopic analysis of simulated singlet oxygen deposition shows that in no case do any subpopulations of tumor cells receive a threshold dose. Indeed, under the conditions of these simulations more than 90% of the tumor volume receives a dose that is approximately 20-fold lower than the threshold dose for mTHPC. Thus, in this evaluation of mTHPC-PDT at various drug-light intervals, any PDT dose metric that is proportional to singlet oxygen creation and/or deposition would fail to predict the tumor response. In situations like this one, other reporters of biological response to therapy would be necessary.
Wang
Ken Kang-Hsin
KK
Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA.
Mitra
Soumya
S
Foster
Thomas H
TH
D000465:Algorithms; D000818:Animals; D003198:Computer Simulation; D004195:Disease Models, Animal; D008652:Mesoporphyrins / Q000627:therapeutic use*; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011829:Radiation Dosage; D026082:Singlet Oxygen / Q000378:metabolism; D013997:Time Factors
D008652:Mesoporphyrins; D017319:Photosensitizing Agents; D026082:Singlet Oxygen; C072269:temoporfin
Photochem Photobiol. 2005 Jan-Feb;81(1):196-205
15469385
J Photochem Photobiol B. 2005 Jun 1;79(3):231-41
15896650
Neoplasia. 2008 May;10(5):429-38
18472960
Br J Cancer. 1997;76(8):1021-8
9376261
Proc R Soc Lond B Biol Sci. 1964 Dec 15;161:247-74
14224411
Cell Death Differ. 2002 Sep;9(9):934-44
12181744
Photochem Photobiol. 2005 Jul-Aug;81(4):849-59
15807635
Br J Cancer. 2003 Jan 27;88(2):283-90
12610515
Radiat Res. 2003 Oct;160(4):452-9
12968929
Photochem Photobiol. 1997 Jan;65(1):135-44
9066293
Photochem Photobiol. 2005 Sep-Oct;81(5):1123-30
15971933
Photochem Photobiol. 2003 Dec;78(6):615-22
14743872
Lasers Surg Med. 2006 Jun;38(5):509-15
16788921
Radiat Res. 1998 Nov;150(5 Suppl):S146-56
9806617
Head Neck. 2004 Mar;26(3):232-40
14999798
Clin Cancer Res. 2005 May 1;11(9):3543-52
15867258
Photochem Photobiol. 2002 Mar;75(3):289-95
11950095
Cancer Res. 1996 Jul 1;56(13):2908-11
8674038
Cancer Res. 1985 Feb;45(2):572-6
3967232
Photochem Photobiol. 2006 Sep-Oct;82(5):1198-210
16808593
Photochem Photobiol. 2005 Sep-Oct;81(5):1161-7
15934792
Cancer Res. 2000 Mar 15;60(6):1637-44
10749134
Photochem Photobiol. 1998 Sep;68(3):281-8
9747583
Photochem Photobiol Sci. 2002 Sep;1(9):690-5
12665307
Nat Med. 2003 Oct;9(10):1327-31
14502284
Photochem Photobiol. 2002 Mar;75(3):282-8
11950094
Photochem Photobiol. 2001 Mar;73(3):297-303
11281027
Lancet Oncol. 2004 Aug;5(8):497-508
15288239
Photochem Photobiol. 1999 Jan;69(1):61-70
10063801
Opt Lett. 2003 May 1;28(9):695-7
12747710
Med Phys. 2004 Jul;31(7):1949-59
15305445
Med Phys. 2007 Jan;34(1):282-93
17278514
J Biomed Opt. 2001 Oct;6(4):457-67
11728206
Br J Cancer. 2003 Jul 21;89(2):398-404
12865935